 PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. Lucid, has entered into a sponsored research agreement with the Fred Hutchinson Cancer Research Center Fred Hutchinson at the University of Washington in Seattle, WA to evaluate Barretts Esophagus BE progression biomarkers in patients using Lucids EsoCheckTM Esophageal Cell Collection Device with CollectProtectTM Technology. The agreement covers a research program entitled Biomarkers for the Detection of Cancer led by principal investigator William M. Grady, M.D. AGAF. 